



*In Search of Better Health*

# KENYA MEDICAL RESEARCH INSTITUTE

## OFFICE OF THE DIRECTOR RESEARCH & DEVELOPMENT

Tell: +254 020 2722541, 2713349,  
0722 205 901, 0733 400 003

P.O. Box 54840-00200, Nairobi  
Email: ddr@kemri.go.ke

Website: [www.kemri.go.ke](http://www.kemri.go.ke)

**KEMRI/RES/7/3/1**

**August 29, 2022**

**TO: DR. AMBROSE AGWEYU,  
PRINCIPAL INVESTIGATOR.**

**THROUGH: THE DEPUTY DIRECTOR, CGMR-C,  
KILIFI.**

Dear Sir,

**Re: PROTOCOL NO. KEMRI/SERU/CGMR-C/203/4085 (REQUEST FOR  
AMENDMENT 4): SURVEILLANCE AND EPIDEMIOLOGIC EVALUATION OF  
COVID-19 IN KENYA.**

This is to inform you that during the 326<sup>th</sup> Committee C meeting of the KEMRI Scientific Ethics Review Unit (SERU) held on **August 25, 2022**, the request for an amendment to the above referenced research proposal was discussed.

The committee reviewed the following attached documents;

1. Quick turnaround review request form
2. SERU amendment submission form
3. Current SERU approval letter dated 16 August 2021
4. Forwarded cover letter for annual renewal request\_2022-2023 dated 13 July 2022
5. Surveillance and epidemiological evaluation of COVID-19 in Kenya (SEECK) protocol version 2.4; 04 July 2022 (tracked and highlighted)
6. Surveillance and epidemiological evaluation of COVID-19 in Kenya (SEECK) protocol version 2.4; 04 July 2022 (clean)
7. Sero-surveillance HDSS information sheets and consent/ assent forms version 2.2; 04 July 2022 (English, Swahili and Giriama; tracked and clean)
8. Translation certificate\_ signed
9. Research ethics certificate for additional investigator (1)

The committee noted the following amendments:

1. To add a clinical epidemiologist, Dr. Makobu Kimani as a co-investigator (pages 2 and 95).
2. To add collection of dried blood spot (DBS) samples in about 10% of the individuals participating in SARS-CoV-2 serological surveillance among residents of Health and Demographic Surveillance System (HDSS) sites (pages 11, 13, 26, 30, 60, 65, 66, 72 and HDSS serosurveillance consent documents) as well as associated costs (page 81).
3. To change the study contact listed in the informed consent documents for the SARS-CoV-2 serological surveillance among HDSS residents from Prof. Ifedayo Adetifa to Dr. Wangeci Kagucia (HDSS serosurveillance consent documents).

The Committee concluded that the suggested amendments are justified and do not alter the substance of the study therefore **granted approval** for implementation.

Please note that you are required to submit any further requests for changes to the approved protocol to the SERU for review and approval prior to implementing any additional changes.

Yours faithfully,

**ENOCK KEBENEI,  
THE ACTING HEAD,  
KEMRI SCIENTIFIC AND ETHICS REVIEW UNIT**